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Identity 
Other names: ALS9; HEL168; MGC22466; 
MGC71966; RNASE4; RNASE5 




     
 
Starts at 2152336 and ends at 2162345 in NCBI reference 
sequence NT_026437.12. Gene map locus is available at NCBI 
Nucleotide. Total length of ANG DNA is 10010 nucleotides. The 
coding region starts at 2162723 and ends at 2162166 including 
stop codon TAA. 
Protein 
Description 
The amino acid sequence is available at NCBI protein 
locus AAA51678. It consists of a signal peptide from 
amino acid 1 to 24 and a mature peptide from amino 
acid 25 to 147. 
ANG is a basic, single chain potent blood-vessel 
inducing protein with a molecular weight of 14 kDa 
which was originally discovered in conditioned media 
of a human colon carcinoma cell line HT-29. ANG  
 
belongs to the RNAse superfamily, being  
35% identical and 68% homologous to the pancreatic 
RNAse A sequence. The overall crystal structure of 
ANG shows a similarity to, but the biological actions of 
ANG differ distinctly from those of RNAse A. ANG 
possesses two distinct regions: a ribonucleolytic and a 
noncatalytic site, both being critical for angiogenic 
activity. Besides the ribonucleolytic activity, ANG 
differs from RNAse A in noncatalytic activities such as 
interactions with endothelial and smooth muscle cells 
and subsequent cellular responses in the events of 
neovascularization, including basement membrane 
degradation, signal transduction, and nuclear 
translocation. 
Expression 
ANG mRNA is expressed in a wide spectrum of cells 
including neoplastic cells as well as normal epithelial 
cells, fibroblasts, peripheral blood cells, and vascular 
endothelial cells. 
Localisation 
Strikingly, ANG localizes freely in the circulation, and 
is translocated into the nucleus. Nuclear translocation 
of ANG triggers subsequent cell proliferation. 
However, the precise mechanisms for why serum ANG 
is inactive and continuous angiogenesis does not take 
place remain unknown. 
Function 
I. Ribonuclease activity 
The catalytic activity of ANG is several orders of 
magnitude weaker than that of RNAse A, this being 
partly due to the partial occupation of the pyrimidine-
binding pocket of RNAse A by glutamine-117 residue 
so that the substrate binding is compromised. Key 
amino acids for the ribo- 
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The secondary structure elements of human ANG are depicted by purple boxes. The numbers on the upper and lower sides of each 
element indicate respectively the beginning and end amino acid residue positions (Acharya et al., 1994). The whole amino acid 
sequences are shown below and the signal peptide sequences (1-24) are enclosed by box. The H elements form helix structure (Acharya 
et al., 1994). Key amino acids for the ribonucleolytic activity of ANG (His13, Lys40, and His114) are indicated by plus (+) signs, and 
residues necessary for angiogenesis (60-68 and 109) are underlined. 
 
nucleolytic activity of ANG are His13, Lys40, or 
His114 of ANG, a catalytic triad, but mutations of 
these amino acids also reduce ANG induced 
angiogenesis, suggesting that the ribonucleolytic 
activity of ANG, although weak, is necessary for the 
angiogenic activity of ANG. Furthermore, several 
arginines are essential for ribonucleolytic and 
angiogenic activities. 
II. Angiogenic activity 
In addition to the catalytic activity, cell binding sites 
which encompass residues 60-68 of the surface loop as 
well as asparagine-109 are necessary for angiogenesis. 
The variants undergoing alterations of these residues 
lack any angiogenic activity while the enzymatic 
activity remains intact. Inversely, replacing the surface 
loop in RNAse A (residues 59-73) with the 
corresponding region of ANG (residue 57-70) bestows 
a neovascularization activity to the RNAse A. 
1) Basement membrane degradation 
Amino acid residues from Lys60 to Asn68 of the ANG 
constitute a cell surface receptor binding site. 
Accordingly, a 42 kDa endothelial cell surface protein 
was identified as an ANG binding protein, which was 
later found to be a smooth muscle type alpha-actin. The 
ANG-actin complex dissociates from the cell surface 
and activates a tissue type plasminogen activator, thus 
accelerating degradation of the basement membrane 
and extracellular matrix that allows endothelial cells to 
penetrate or migrate through the extracellular matrix 
more easily, an initial step of neovascularization. 
Furthermore, fibulin-1, an important molecule for 
stabilization of the blood vessel wall, binds to ANG, 
suggesting that the ANG-fibulin-1 complex modulates 
new blood vessel formation and stabilization. 
2) Signal transduction 
Besides the 42 kDa ANG receptor, a 170 kDa molecule 
later found on the endothelial surface is responsible for 
signal transduction, an important process leading to cell 
proliferation. ANG activates several secondary 
message cascades such as extracellular signal related 
kinase 1/2 (ERK1 and ERK2), protein kinase B/Akt, 
and stress-associated protein kinase/c-Jun N-terminal 
kinase (SAPK/JNK). 
3) Nuclear translocation 
The nuclear mechanisms underlying the function of 
ANG remain elusive. Internalization could involve cell 
surface ANG binding to proteins as well as to other 
molecules such as proteoglycans, followed by 
endocytosis. In this event, ANG interacts directly with 
intracellular protein alpha-actinin-2 followed by 
translocation into the nucleus through the nuclear pore 
in a passive manner. After nuclear retention, ANG 
binds to carrier proteins through a sequence 29-
IMRRRGL-35 (nuclear localization signal) of ANG 
and to the ANG-binding element of ribosomal DNA 
(CTCT repeats) and subsequently, stimulates ribosomal 
RNA transcription. Nuclear translocation is essential 
for cell proliferation since it is considered a third 
messenger and promotes gene activation and 
transcription events, and inhibition of the nuclear 
translocation of angiogenin abolishes ANG-induced 
angiogenesis. Interestingly, the expression of cell 
surface receptors responsible for internalization as well 
as for the nuclear translocation of ANG also depends 
on the cell density. 
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III. Roles of ANG in physiological angiogenesis 
The above biological events, which are distinct from 
those of RNAse A, are regulated tightly by the cell 
density-dependent expression of ANG receptors. The 
discovery of the uniquely regulated expression of ANG 
receptors provides us with the following conceivable 
mechanisms for ANG related angiogenesis. In the 
region where neovascularization is required, ANG 
binds to the endothelial surface 42 kDa receptor, and 
the ANG-42 kDa receptor complex dissociates from the 
cell surface and stimulates proteolytic activity, thus 
facilitating the penetration of endothelial cells through 
the extracellular matrix. After the leading cells migrate 
away, the endothelial cell density in the vicinity of 
migrating cells might be sparse, and such cell sparsity 
triggers the endothelial proliferation machinery that 
includes signal transduction, ANG internalization, and 
nuclear translocation. A 170 kDa receptor is one of the 
receptors responsible for this orchestrated process. 
Once the microenvironment is filled up with the 
sufficient amount of endothelial cells and the vascular 
network is established, such cell proliferating events 
diminish. Therefore, the above cell density dependent 
biological events are intelligent mechanisms where the 
proliferation machinery and subsequent angiogenic 
switch are on when neovascularization is needed while 
they are off to prevent unwanted angiogenesis. 
Homology 
Of the 123 amino acids of human ANG, 43 (35%) and 
25 are respectively identical to human pancreatic 
RNAse or to other RNAse, and 16 are conservative 





There is growing evidence that increased ANG 
expression in tissue and/or in sera is correlated with 
tumor aggressiveness. These facts are explained at least 
in part by the hypothesis that ANG in malignancy plays 
roles in the proliferation and migration of malignant 
cells, mimicking endothelial cell behavior during 
physiological angiogenesis. As described earlier, ANG 
could activate proteolytic activity, so that ANG-
expressing malignant cells are allowed to invade 
through the extracellular matrix and enter into the 
bloodstream. In addition, the continuous translocation 
of ANG to the nucleus of HeLa cells in a cell density-
independent manner suggests that cancer cells are also 
targets for ANG, and that ANG per se is a contributing 
factor for sustained cell growth and the constant supply 
of ribosomes, a characteristic of malignant cells. 
Several ANG antagonists have been introduced and 
some have proved to be effective inhibitors for the 
 
 
establishment or metastasis of human tumors in 
athymic mice. These compounds include a monoclonal 
antibody, antisense oligonucleotides complementary to 
the AUG translational start site region of ANG, 
translocation blocker, enzymatic inhibitor targeting 
ANG enzymatic active site, ANG binding polypeptide 
complementary to the receptor binding site of ANG, 
and internalization pathway blocker. 
Female breast cancer 
Disease 
Female breast cancer is globally the most common 
cancer with an annual incidence of 1,15 million 
worldwide. It is also the leading cause of death, with a 
mortality rate of 133 per million. Breast cancer 
incidence rates have increased in most geographic 
regions. 
Prognosis 
The ANG level in sera and the roles of ANG in breast 
cancer patients seem to be conflicting. Some studies 
found significantly increased serum ANG in breast 
cancer patients in comparison with normal controls 
while other studies failed to find such a difference. The 
serum ANG level is significantly decreased after breast 
cancer resection, suggesting that the source of ANG is 
at least in part the breast cancer cells. However, there is 
conflicting evidence concerning the role of ANG. The 
correlation between ANG expression in tissue or in sera 
and patient survival was inverse, neutral, or even 
positive. The absence of any increase in serum ANG 
levels in early stage breast cancer patients suggests that 
ANG may have clinical implications when breast 
cancer progresses to the advanced stage. 
Pancreas cancer 
Disease 
The pancreas is composed of exocrine (acinar glands 
and pancreas duct) and endocrine (islets of Langerhans) 
components. Both can give rise to malignant 
neoplasms, but adenocarcinoma arising from the 
pancreatic ducts is representative of all pancreatic 
cancers. 
Prognosis 
Pancreatic cancer is one of the most aggressive diseases 
with most cancers already in later stages at 
presentation, the 5-year survival rate being around 5% 
both in USA and in Europe. Investigations concerning 
ANG expression in pancreatic cancer are scarce. ANG 
in sera is elevated in pancreatic cancer patients as 
compared with healthy volunteers, and increased ANG 
mRNA in tissue or increased ANG in sera has been 
correlated with cancer aggressiveness. In addition, the 
involvement of ANG in the cancer microenvironment 
has been suggested by findings of the ANG expression 
in chronic pancreatitis adjacent to pancreatic cancer but 
not in pure chronic pancreatitis. Cancer derived 
fibroblasts also express ANG. 
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Gastric cancer 
Disease 
Gastric cancer, the third most common cancer and the 
second leading cause of cancer death among men, 
arises in an estimated one million new cases in both 
sexes worldwide. Gastric cancer is anatomically 
classified as noncardia and cardia cancers, and the 
former incidence has declined while the latter incidence 
has increased. Helicobacter pylori infection is one of 
the risk factors for noncardia cancer. Adenocarcinomas 
account for a large majority of gastric cancer histologic 
diagnoses. 
Prognosis 
The 5-year survival rate of gastric cancer in Japan is 
double that of the United States and Europe. The better 
treatment outcomes are ascribed partly to the social 
screening program that attempts to capitalize on the 
benefit of early detection, and partly to systematic 
lymph node dissection. ANG in sera is increased in 
gastric cancer patients and is decreased by resection, 
suggesting gastric cancer to be a source of ANG. 
Increased mRNA expression in gastric cancer tissues or 
increased serum ANG levels is correlated with cancer 




Colon cancer is the fourth most commonly diagnosed 
cancer and fourth most frequent cause of cancer death 
among men. Colon cancer incidence rates have 
increased in most parts of the world. Typically, there is 
a pathologic evolution from benign adenomas to cancer 
(adenoma-carcinoma sequence), so that colorectal 
cancer screening aims to detect lesions at the adenoma 
stage and interrupt the adenoma carcinoma sequence, 
ultimately reducing colorectal cancer incidence and 
mortality. 
Prognosis 
Colorectal cancer exhibits increased serum ANG 
concentration, and the degree of elevation is correlated 
with cancer progression. ANG message expression in 
colorectal cancer tissue has also been correlated with 
poor patient survival. 
Cytogenetics 
Overexpression of the 14q11.1-14q11.2 product was 
observed in a colon adenocarcinoma cell line. 
Lung cancer 
Disease 
Lung cancer is the most frequently diagnosed cancer 
among men. The mortality rate is the highest among 
men and the second highest among women worldwide. 
Cigarette smoking is the most important risk factor for 
lung cancer. The main histologic types of lung cancer 
are adenocarcinoma, squamous cell carcinoma, large 
cell carcinoma, and small cell carcinoma. The stage of 
the disease is a strong predictor of survival, suggesting 
that early detection is needed for improvement in 
treatment outcomes. 
Prognosis 
Immunoreactivity in lung cancer tissue is correlated 
with tumor size and positive nodal involvement. 
Recently, the detection of ANG in exhaled breath 
condensate has been achieved, and breath based ANG 
may help in the early detection of lung cancer. 
Cytogenetics 
DNA damage in 14q11.2 was found in asbestos-
exposed lung cancer patients. 
Liver cancer 
Disease 
The global incidence and mortality rate of liver cancer 
is ranked among top 5 (in men) and top 10 (in women) 
cancer types. The hepatitis B virus and hepatitis C virus 
are the most important risk factors for liver cancer. 
Histologic classification separates hepatocellular 
carcinoma (HCC) (liver cell origin) from 
cholangiocarcinoma, which arises from intrahepatic 
bile ducts. HCC is the most common histology of liver 
cancer which is characterized by vigorous 
neovascularization. 
Prognosis 
The serum ANG is increased in hypervascular 
hepatocellular carcinoma. The serum ANG level 
decreases after therapy but again increases at 
recurrence, suggesting the usefulness of serum ANG 
measurement for monitoring the disease and prediction 
of patient survival. However, other investigators found 
a neutral correlation between serum ANG and survival. 
The ANG immunoreactivity is correlated with poorer 
histological differentiation. 
Cytogenetics 




Prostate cancer is the second most frequently diagnosed 
cancer among men. Prognosis is excellent for early 
stage disease while it is poor for those diagnosed with 
advanced cases, pointing to the benefit of earlier 
diagnosis. Measurement of prostate specific antigen 
helps to detect biologically indolent prostate cancer. 
Prognosis 
The immunoreactivity of ANG is more evident 
according to prostate epithelial cells evolution from a 
benign to an invasive phenotype. In vitro analyses 
using prostate cancer cell line have elucidated that 
ANG is one of the elements responsible for 
tumorigenicity and tumor growth. Furthermore, serum 
ANG is more increased in hormone-refractory patients 
than in healthy controls. 
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Leukemia 
Disease 
Leukemias are malignancies that affect blood-forming 
stem cells in the bone marrow. Leukemia, a 
heterogeneous group of malignancies, is classified into 
several subtypes according to the major cell type such 
as acute lymphoblastic leukemia (ALL), chronic 
lymphoblastic leukemia (CLL), acute myeloid 
leukemia (AML), chronic myeloid leukemia (CML), 
etc. Acute types refer to cancers arising in immature 
stem cells while chronic types refer to cancers arising 
in mature stem cells. 
Prognosis 
The ANG level in sera was increased in AML and 
CML, although other investigators failed to find such 
correlation. In sharp contrast to the clinical significance 
of serum ANG in other solid tumors, elevated serum 
ANG in AML and CML is correlated with better 
patient survival. 
Cytogenetics 
14q11.2 is one of the risk foci for ALL. 
Hodgkin and non-hodgkin lymphomas 
Disease 
Lymphomas, malignancies of the lymphoid cells, are 
divided on the basis of their pathologic features into 
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma 
(NHL). HL almost always develops in a lymph node or 
other lymphoid structure and spread to nearby nodes. 
HL is characterized by the presence of Hodgkin Reed 
Sternberg cells. It is one of the most common cancers 
diagnosed in younger persons. The proportions of 
patients being diagnosed below 50 years old accounts 
for 60%. NHL occurs in more elderly patients in the 
context of HIV-related immunosuppression. NHL with 
HIV shows extensively poorer survivals than those 
without HIV. 
Prognosis 
In sharp contrast to the other solid malignancies, serum 
ANG concentrations in patients with HL or NHL are 
less than or the same as those in healthy controls. 
Increased serum ANG renders no or an inverse impact 
on survival in NHL patients. 
Cytogenetics 
One subtype of NHL experiences multiple 
translocations at 14q11.2. 
Kidney and bladder cancer 
Disease 
Kidney and bladder cancers are placed among the top 
ten cancer types in both sexes. Cancer of the urinary 
bladder most commonly originates in the urothelium, 
the epithelium that lines the bladder. Bladder cancer 
incidence is significantly higher in males than in 
females. There are three major histologic types of 
bladder cancer: transitional cell carcinoma, squamous 
cell carcinoma, and adenocarcinoma, the former being 
overwhelmingly the most common. The majority of 
cancers of the kidney are renal cell carcinomas, which 
arise from renal tubules. On the other hand, cancer of 
the renal pelvis designated as transitional cell 
carcinoma comprises the minority. 
Prognosis 
The serum level of ANG is increased in renal cell 
carcinoma and bladder cancer; however, the increase in 
serum ANG level does not correlate with patient 
survival for renal cell carcinoma. On the other hand, 
increased serum ANG or ANG message in urothelial 
cancer correlates with poor patient survival or cancer 
progression. Recently, ANG in the urine has been 
found to be increased in bladder cancer patients. 
Melanoma 
Disease 
Melanoma is placed as the leading cause of skin cancer 
death and its incidence has dramatically increased over 
the last ten years. It is characterized as having a 
notorious resistance to currently available therapies so 
that early detection and intervention is needed. 
Prognosis 
Survival clearly worsens with increasing tumor 
thickness. Thin lesions exhibit excellent survival 
outcomes while the MST of patients with advance 
cases is around 8 months. The ANG in sera is increased 
in melanoma patients, and increased serum ANG 
correlates with malignancy potential, accordingly, 
ANG contributes directly to A375 melanoma cell 
proliferation. However, other investigators failed to 
find such a correlation. 
Gynecological cancers 
Disease 
Cancers of the uterus and ovary are respectively the 
second and the sixth most frequently diagnosed cancer 
among women. Cancer of the uterus is further 
classified as cancer of the cervix and corpus, and 
cancer of the cervix uteri shows the highest incidence 
among the three gynecological malignancies. Cancer of 
the cervix uteri can be attributed to persistent infection 
with carcinogenic genotypes of human papilloma virus. 
The three most common histological types of cancer of 
the cervix uteri are squamous, adenosquamous, and 
adenocarcinoma. Adenocarcinoma is the most common 
histology of cancer of the corpus uteri and ovary. 
Women with ovarian cancer have poorer survival rates 
than those with other gynecological cancers. 
Prognosis 
Serum ANG is significantly increased in ovarian cancer 
patients, while other studies failed to find such a 
difference. Increased serum ANG concentration is 
correlated with cancer progression in ovary and cervix 
uteri. 
Cytogenetics 
Gains on 14q11.2 are associated with chemoresistant 
ovarian cancer. 
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